Ryjunea, containing atropine sulfate, is an eye drop solution primarily used to slow down the progression of myopia (short-sightedness) in children aged 3 to 14 years. It is specifically indicated for cases of rapidly progressing myopia (at least 0.5 dioptres per year) within a defined range of severity (–0.5 D to –6.0 D). Ryjunea is the first low-dose atropine eye drop approved in the EU for this specific indication. It works by blocking muscarinic receptors, although the exact mechanism by which it slows myopia progression is still under scientific investigation.